hemolyt
anemia
imha
dog
cat
associ
high
morbid
pathogen
autoantibodi
target
erythrocyt
membran
provid
mechan
fraction
crystalliz
extravascular
hemolysi
mediat
complement
interact
antibodi
bound
erythrocyt
facilit
extravascular
hemolysi
caus
intravascular
hemolysi
format
membran
attack
complex
expediti
diagnosi
distinguish
imha
caus
anemia
critic
rapid
institut
appropri
treatment
variou
criteria
diagnosi
imha
describ
literatur
base
document
erythrolysi
proxi
marker
littl
consensu
exist
criteria
requir
definit
diagnosi
furthermor
differenti
spontan
imha
diseas
associ
put
trigger
factor
import
first
step
diagnost
evalu
remov
trigger
factor
whenev
possibl
crucial
compon
treatment
howev
guidelin
exist
diagnost
assess
trigger
factor
formal
assess
evid
implic
imha
lack
evid
summari
would
allow
clinician
better
gaug
likelihood
given
comorbid
implic
pathogenesi
imha
would
help
guid
diagnost
test
perform
individu
patient
object
consensu
statement
therefor
present
guidelin
fundament
diagnosi
imha
test
screen
put
trigger
factor
base
evid
infer
parallel
data
human
medicin
expert
opinion
work
contribut
consensu
statement
complet
member
consensu
panel
addit
member
relev
veterinari
compar
clinic
immunolog
societi
vcci
task
forc
establish
search
databas
medlin
web
scienc
relev
refer
april
march
standard
boolean
search
term
allow
lemmat
adopt
refer
captur
algorithm
anemia
anaemia
dog
cat
immun
hereaft
denot
import
refer
manag
softwar
mendeley
elsevi
new
york
endnot
clariv
analyt
philadelphia
manual
screen
basi
inclus
criteria
outlin
support
inform
refer
list
paper
also
examin
captur
refer
cite
medlin
web
scienc
search
conduct
captur
addit
refer
support
inform
total
paper
captur
search
algorithm
abstract
paper
review
oag
lk
uj
alm
sb
bg
rg
js
lead
reject
paper
fail
meet
inclus
criteria
duplic
paper
exclud
yield
uniqu
paper
addit
paper
exclud
includ
inform
patient
potenti
trigger
factor
remain
paper
contain
inform
relev
infecti
diseas
includ
genera
microb
infect
dog
genera
microb
infect
cat
search
basi
genera
yield
addit
paper
meet
inclus
criteria
search
perform
march
use
algorithm
yield
anoth
paper
import
paper
publish
advent
onlin
archiv
ad
list
data
therefor
extract
paper
figur
design
novel
qualiti
assess
data
extract
tool
includ
domain
captur
inform
studi
design
qualiti
q
confid
comorbid
diagnosi
c
likelihood
causal
link
comorbid
imha
l
confid
imha
diagnosi
number
patient
given
comorbid
n
purpos
studi
term
comorbid
includ
exposur
drug
toxin
vaccin
addit
domain
captur
detail
inform
comorbid
includ
statist
infer
avail
comorbid
summar
broad
categori
infecti
diseas
cancer
inflammatori
diseas
drug
toxin
vaccin
panel
member
vcci
task
forc
member
assign
random
pair
purpos
data
extract
qualiti
assess
divid
total
number
paper
equal
among
pair
concord
among
pair
sought
individu
member
disagre
specif
observ
observ
relat
qualiti
assess
confirm
lk
oag
comorbid
identifi
paper
integr
metric
evid
ime
comput
sum
normal
score
weight
accord
assess
rel
import
evid
rate
long
comorbid
present
individu
patient
henc
ime
q
c
n
comorbid
present
individu
patient
includ
infect
agent
ime
valu
calcul
refer
patient
nevertheless
made
narr
yield
insight
score
assess
posit
question
studi
ask
whether
comorbid
induc
associ
imha
part
hypothesi
specif
aim
question
comorbid
induc
associ
imha
answer
studi
design
answer
ye
score
assign
answer
studi
design
descript
associ
comorbid
assign
arbitrari
score
lowest
possibl
maximum
q
score
comput
comorbid
assign
descript
associ
gener
studi
qualiti
case
irrelev
question
causal
relationship
comorbid
imha
q
score
case
therefor
maximum
normal
score
criterion
yield
maximum
ime
valu
minimum
ime
valu
appli
studi
present
evid
comorbid
associ
imha
comorbid
within
paper
conserv
score
ime
criteria
appli
relev
cohort
patient
avoid
exagger
evid
threshold
ime
valu
comput
allow
comorbid
design
neglig
low
intermedi
high
evid
causal
relationship
imha
threshold
neglig
low
evid
taken
hypothet
descript
associ
studi
intermedi
c
l
score
posit
case
ime
threshold
low
intermedi
evid
taken
hypothet
studi
q
score
intermedi
c
l
score
posit
case
ime
final
threshold
intermedi
high
evid
taken
hypothet
prospect
studi
q
score
high
c
score
intermedi
l
score
high
score
mechanist
base
posit
case
ime
qualiti
assess
data
extract
tool
shown
support
inform
support
inform
show
deriv
score
q
c
l
n
panel
member
draft
recommend
assign
area
draft
recommend
subject
round
delphi
review
panel
member
abl
give
written
feedback
everi
recommend
use
onlin
questionnair
survey
monkey
san
mateo
california
end
round
suggest
incorpor
work
templat
facilit
recommend
consensu
yet
reach
includ
subsequ
delphi
cycl
round
review
unanim
consensu
reach
major
recommend
differ
opinion
remain
indic
text
consensu
statement
oag
lk
uj
amm
sb
assign
section
work
document
edit
incorpor
comment
gener
oral
present
section
edit
submiss
acvim
review
member
draft
consensu
statement
also
submit
european
colleg
veterinari
intern
medicin
american
colleg
veterinari
emerg
critic
care
european
colleg
veterinari
emerg
critic
care
american
colleg
veterinari
patholog
european
colleg
veterinari
clinic
patholog
solicit
comment
member
feedback
specialist
colleg
use
panel
member
produc
final
consensu
statement
spun
pcv
suggest
calcul
hematocrit
may
unreli
agglutin
howev
studi
human
report
increas
plasma
trap
abnorm
erythrocyt
eg
spherocyt
could
introduc
inaccuraci
spun
best
knowledg
effect
agglutin
spherocytosi
spun
pcv
investig
veterinari
speci
lack
regener
assess
reticulocyt
count
elimin
imha
approxim
dog
anemia
spherocyt
use
diagnost
criterion
dog
felin
erythrocyt
consist
display
central
pallor
interpret
spherocyt
blood
transfus
done
cautious
store
blood
product
may
contain
high
proport
spherocyt
document
human
patient
hemolyt
transfus
spherocytosi
assess
monolay
blood
smear
artifact
aris
toward
feather
edg
thick
anem
anim
spherocyt
confirm
deeper
monolay
avoid
artifact
thin
area
spherocytosi
also
induc
increas
osmot
osmot
fragil
test
influenc
factor
eg
erythrocyt
panel
advoc
routin
use
diagnosi
imha
report
caus
spherocyt
morpholog
similar
pyknocyt
elimin
includ
oxid
damag
eg
hypersplen
eg
hepatosplen
lymphoma
pyruv
kinas
disord
associ
erythrocyt
fragment
eg
microangiopath
hemolyt
disord
includ
hemolyt
urem
syndrom
hereditari
spectrin
defici
also
potenti
may
give
rise
spherocyt
smear
made
blood
store
percentag
spherocyt
blood
smear
human
patient
mutat
caus
hereditari
spherocytosi
variabl
literatur
search
canin
hereditari
spherocytosi
identifi
case
mark
spherocytosi
singl
studi
oil
immers
field
yield
sensit
confid
interv
ci
ci
provid
author
onlin
medcalc
diagnost
test
evalu
calcul
http
wwwmedcalcorgcalcdiagnostictestphp
use
calcul
specif
ci
imha
compar
sensit
ci
specif
ci
c
oil
immers
threshold
oil
immers
field
therefor
could
consid
support
diagnosi
imha
oil
immers
field
also
may
consist
imha
provid
caus
spherocytosi
identifi
threshold
similar
criteria
spherocytosi
propos
semiquantit
grade
spherocyt
number
low
versu
typic
abund
extravascular
imha
variabl
among
field
could
issu
calcul
mean
count
sever
field
eg
could
help
establish
true
extent
spherocytosi
enrol
case
imha
research
blood
smear
use
given
pitfal
spherocyt
recognit
examin
smear
clinic
pathologist
advantag
although
evalu
dri
blood
smear
hematolog
instrument
scatter
suggest
agglutin
panel
consid
techniqu
adequ
confirm
agglutin
base
possibl
overlap
rouleaux
blood
smear
potenti
caus
macrocyt
scattergram
salin
agglutin
test
perform
mix
drop
salin
drop
blood
report
specif
ci
c
imha
mix
blood
salin
yield
specif
ci
c
base
dog
without
imha
ci
c
anem
dog
agglutin
persist
mix
drop
blood
drop
salin
therefor
consid
adequ
evid
agglutin
consider
higher
dilut
ratio
aid
microscop
identif
agglutin
decreas
fals
posit
confirm
agglutin
persist
wash
erythrocyt
time
ratio
recommend
anim
equivoc
result
eg
rare
small
erythrocyt
clump
otherwis
neg
test
markedli
increas
total
protein
eg
leishmaniasi
multipl
myeloma
felin
infecti
periton
fip
fibrinogen
strong
rouleaux
format
blood
smear
examin
base
report
agglutin
wash
erythrocyt
normal
dog
suggest
salin
solut
room
temperatur
five
panel
member
prefer
direct
coomb
test
dat
consid
flow
cytometri
dat
equal
use
support
inform
provid
recommend
perform
test
dat
perform
agglutin
persist
wash
combin
anemia
hemolysi
persist
agglutin
suffici
diagnosi
imha
immunochromatographi
offer
altern
convent
dat
flow
cytometri
confirm
neg
result
convent
dat
may
advis
frequent
weak
posit
test
strip
dat
sensit
rang
studi
report
reli
dat
alon
diagnosi
imha
report
sensit
suffici
inform
calcul
specif
dat
studi
publish
report
specif
suffici
inform
calcul
although
small
experiment
studi
report
sensit
flow
sensit
ci
c
larger
studi
report
result
routin
clinic
studi
includ
clinic
ill
neg
control
specif
flow
cytometri
ci
c
ci
report
sampl
handl
effect
flow
cytometri
lack
storag
sampl
day
dat
test
accept
unless
laboratori
advis
current
data
although
limit
suggest
although
immunosuppress
immedi
result
neg
interindividu
variabl
exist
time
requir
becom
neg
dat
initi
flow
cytometri
anecdot
report
suggest
immunosuppress
decreas
percentag
therefor
possibl
recommend
collect
sampl
dat
flow
cytometri
initi
treatment
studi
effect
prior
blood
transfus
dat
flow
cytometri
lack
base
report
result
dog
prior
blood
transfus
absolut
contraind
test
howev
posit
dat
report
dog
without
sign
imha
histori
multipl
furthermor
delay
serolog
hemolyt
transfus
reaction
posit
dat
report
therefor
possibl
recommend
collect
sampl
dat
blood
transfus
suggest
advantag
flow
cytometri
compar
dat
gener
quantit
result
potenti
allow
monitor
therapeut
success
statist
associ
report
laboratori
clinic
featur
percentag
howev
clinic
valu
percentag
posit
erythrocyt
evalu
dog
spherocyt
assess
describ
provid
evid
hemolysi
consist
evid
phenomenon
human
increas
rigid
spherocyt
result
entrap
within
spleen
subsequ
extravascular
absenc
decreas
function
hepat
mass
obstruct
cholestasi
sepsi
hyperbilirubinemia
may
repres
evid
hemolysi
least
follow
consid
suffici
evid
hyperbilirubinemia
icteru
total
serum
plasma
bilirubin
concentr
refer
interv
bilirubinuria
cat
bilirubin
urin
reagent
strip
dog
bilirubin
report
hemolyz
sampl
interpret
combin
inform
regard
like
impact
hemolysi
hemoglobinemia
detect
visual
examin
plasma
measur
hemoglobin
use
indic
hemolysi
limit
individu
method
consid
exampl
spectrophotometr
hemolyt
indic
reli
method
algorithm
directli
compar
among
differ
similarli
discrep
mean
cell
hemoglobin
concentr
cellular
hemoglobin
concentr
provid
advia
hematolog
instrument
may
reflect
hemolysi
sampl
characterist
hemoglobinemia
interpret
evid
hemolysi
elimin
artifactu
hemolysi
common
caus
vitro
hemolysi
includ
limit
traumat
freez
storag
base
studi
human
sampl
via
iv
inject
sampl
likelihood
vitro
hemolysi
increas
factor
increas
erythrocyt
fragil
present
eg
lipemia
provid
caus
myoglobinuria
absent
hemoglobinuria
consid
present
urin
red
discolor
clear
centrifug
posit
heme
reaction
urin
dipstick
present
absenc
intact
erythrocyt
microscop
sediment
examin
assess
hemoglobinuria
perform
use
fresh
urin
sampl
anecdot
likelihood
erythrocyt
lysi
urin
increas
alkalin
poorli
concentr
hyposthenur
urin
sampl
ghost
cell
provid
evid
intravascular
hemolysi
seen
smear
made
immedi
blood
organ
identifi
review
high
intermedi
level
evid
caus
imha
like
induc
diseas
mechan
trigger
erythrocyt
destruct
mani
patient
studi
requir
determin
role
infect
imha
emphas
studi
low
level
evid
repres
lack
studi
design
answer
whether
infect
associ
imha
rather
studi
specif
demonstr
lack
evid
addit
environment
genet
epigenet
factor
play
role
whether
diseas
occur
individu
patient
therefor
clinician
consid
possibl
identifi
recent
recurr
infect
may
contribut
develop
imha
furthermor
elimin
possibl
infect
prudent
immunosuppress
treatment
overal
manuscript
ime
valu
calcul
infecti
agent
type
infect
figur
could
calcul
mani
infecti
agent
either
way
data
summar
eg
number
individu
patient
imha
infect
could
discern
individu
patient
imha
comorbid
support
inform
addit
investig
specif
ask
whether
infect
caus
imha
consensu
summari
statement
present
genera
organ
least
studi
intermedi
higher
level
evid
infect
induc
imha
addit
organ
discuss
support
inform
seventeen
studi
document
case
imha
ime
valu
babesia
speci
whole
rang
median
percent
ime
valu
demonstr
intermedi
high
level
evid
babesia
caus
imha
addit
studi
number
dog
babesia
imha
could
high
level
evid
destruct
erythrocyt
contribut
anemia
dog
infect
b
gibsoni
hemolyt
anemia
document
dog
addit
studi
number
infect
dog
imha
could
determin
provid
use
mechanist
median
ime
valu
rang
babesia
speci
studi
show
intermedi
high
ime
valu
four
studi
dog
experiment
infect
b
gibsoni
yield
median
ime
valu
rang
natur
infect
b
gibsoni
occur
commonli
fight
howev
mix
breed
dog
use
experiment
studi
also
develop
imha
suggest
pathogenesi
larg
driven
whether
speci
babesia
caus
imha
dog
remain
unclear
one
studi
document
imha
chronic
infect
splenectom
mix
breed
dog
experiment
infect
thought
b
gibsoni
later
character
babesia
yield
ime
valu
five
studi
document
case
imha
dog
infect
babesia
cani
median
ime
valu
rang
babesia
voge
document
studi
dog
imha
ime
valu
five
case
imha
document
studi
babesia
dog
although
author
presum
babesia
speci
base
cytolog
examin
blood
smear
geograph
ime
valu
addit
studi
babesia
speci
specifi
like
b
nine
dog
imha
document
studi
ime
valu
thu
evid
larg
babesia
speci
caus
imha
lower
b
gibsoni
attribut
part
fact
studi
design
determin
associ
imha
infect
exist
nevertheless
differ
also
may
exist
pathogen
among
babesia
speci
influenc
risk
imha
exampl
studi
found
major
anem
b
dog
igm
igg
bound
erythrocyt
antibodi
detect
dog
infect
b
studi
eccentrocytosi
suggest
oxid
damag
common
b
dog
ime
valu
b
cani
studi
wherea
b
mechan
erythrocyt
destruct
b
gibsoni
infect
explor
babesia
speci
infect
erythrocyt
antibodi
appropri
target
organ
could
result
erythrocyt
destruct
without
target
howev
antibodi
produc
infect
also
appear
target
erythrocyt
membran
oxid
injuri
may
play
role
antibodi
activ
macrophag
caus
oxid
damag
uninfect
well
infect
erythrocyt
b
gibsoni
infect
factor
may
contribut
sever
imha
addit
oxid
damag
sialic
acid
residu
remov
requir
expos
epitop
target
interestingli
antibodi
develop
dog
experiment
infect
b
gibsoni
attach
undamag
red
blood
cell
dog
recov
clinic
furthermor
vitro
studi
shown
antibodi
reactiv
erythrocyt
higher
age
oxid
fresh
taken
togeth
data
suggest
ongo
damag
red
cell
membran
increas
exposur
epitop
usual
hidden
facilit
erythrocyt
destruct
infect
control
drive
destruct
stop
like
babesia
speci
rangelia
theileria
speci
protozoan
parasit
infect
erythrocyt
dog
studi
dog
experiment
infect
rangelia
vitelli
demonstr
regen
anemia
suspici
imha
develop
infect
treatment
infect
resolv
anemia
without
immunosuppress
retrospect
case
seri
dog
natur
infect
theileria
spp
develop
dog
treat
combin
immunosuppress
imidocarb
dipropion
author
report
resolut
hematolog
abnorm
unspecifi
studi
period
ime
valu
could
calcul
total
number
dog
imha
could
discern
evid
piroplasm
particular
b
gibsoni
caus
imha
intermedi
high
b
gibsoni
evid
suggest
infect
antibodi
target
host
erythrocyt
antigen
expos
consequ
transient
oxid
damag
sialic
acid
residu
remov
studi
need
determin
differ
pathogen
among
speci
host
factor
mediat
risk
develop
imha
infect
dog
known
mechan
erythrocyt
destruct
suggest
immunosuppress
necessari
resolv
erythrocyt
destruct
case
nine
dog
imha
studi
infect
expos
anaplasma
median
ime
valu
rang
addit
imha
antibodi
document
dog
concurr
although
dog
report
treat
concurr
doxycyclin
immunosuppress
corticosteroid
treatment
dog
respond
doxycyclin
treatment
wherea
anoth
dog
prednison
discontinu
one
retrospect
case
seri
document
dog
acut
anaplasma
plati
infect
concurr
dog
spherocytosi
posit
salin
agglutin
coomb
test
result
support
diagnosi
imha
ime
valu
studi
evid
phagocytophilum
caus
imha
low
howev
studi
report
phagocytophilum
dog
imha
limit
case
report
retrospect
studi
design
investig
causal
relationship
presenc
imha
condit
concurr
infect
suggest
prospect
control
studi
examin
possibl
causal
relationship
phagocytophilum
imha
dog
warrant
evid
plati
induc
imha
dog
low
data
limit
singl
retrospect
case
seri
prospect
control
studi
requir
document
possibl
causal
relationship
plati
imha
dog
evid
agent
includ
dirofilaria
immiti
ehrlichia
spp
borrelia
spp
hemotrop
mycoplasma
spp
bartonella
spp
leishmania
infantum
protozo
pathogen
includ
neospora
caninum
bacteri
infect
induc
imha
neglig
low
figur
could
quantifi
base
result
report
support
inform
organ
leishmania
spp
immiti
bartonella
spp
coomb
anemia
observ
commonli
therefor
clinic
perspect
still
import
elimin
infect
agent
dog
imha
differenti
diagnosi
hemolyt
anemia
document
cat
infect
b
feli
studi
south
africa
six
cat
coinfect
felin
leukemia
viru
felv
treatment
b
feli
without
immunosuppress
resolv
imha
yield
ime
valu
although
studi
limit
intermedi
level
evid
found
b
feli
caus
imha
cat
treatment
resolv
imha
without
immunosuppress
seven
studi
document
imha
cat
infect
hemotrop
mycoplasma
spp
yield
ime
median
ime
valu
valu
differ
wide
among
hemotrop
mycoplasma
speci
rang
overal
high
level
evid
exist
haemof
induc
imha
cat
hemolyt
anemia
document
cat
studi
median
ime
valu
rang
two
studi
provid
high
studi
design
answer
whether
infect
caus
studi
cat
experiment
infect
haemof
sever
macrocyt
coomb
anemia
persist
autoagglutin
erythrocyt
develop
contrast
find
occur
cat
infect
less
pathogen
candidatu
ca
mycoplasma
haemominutum
ca
mycoplasma
turicensi
target
antibodi
develop
haemof
infect
cat
investig
serum
cat
infect
haemof
agglutin
infect
erythrocyt
normal
erythrocyt
suggest
babesiosi
damag
erythrocyt
unmask
antigen
contribut
pathogenesi
ca
haemominutum
infect
document
cat
imha
studi
studi
show
associ
imha
yield
median
ime
valu
rang
high
level
evid
found
haemof
caus
imha
cat
neglig
low
level
evid
found
less
pathogen
speci
ca
haemominutum
caus
imha
evid
found
ca
turicensi
induc
imha
whether
coinfect
host
immun
statu
play
role
develop
imha
cat
infect
differ
hemotrop
mycoplasma
speci
requir
studi
seven
studi
meet
inclus
criteria
howev
comorbid
erythroleukemia
myeloprolif
diseas
chronic
interstiti
nephriti
glomerulonephr
splenic
amyloidosi
drug
administr
document
infect
cat
preclud
ime
median
ime
valu
other
rang
collect
evid
felv
infect
induc
imha
low
observ
cat
also
coomb
anemia
prompt
investig
whether
erythrocyt
destruct
contribut
anemia
cat
summari
evid
infect
document
cat
imha
includ
fip
felin
immunodefici
viru
fiv
l
infantum
mycoplasma
gata
haemof
soft
tissu
infect
urinari
tract
infect
provid
support
inform
evid
causal
link
cancer
imha
dog
current
lack
veterinari
literatur
larg
reflect
fact
major
publish
studi
specif
ask
whether
cancer
associ
imha
dog
studi
need
determin
associ
exist
although
evid
causal
link
exist
cancer
elimin
potenti
trigger
diseas
eight
cat
ime
valu
could
calcul
lymphoma
imha
two
studi
report
case
demonstr
causal
associ
imha
studi
consid
partial
report
suggest
latter
report
sibl
specif
experiment
cat
cat
lymphomalymphocyt
leukemia
diagnos
histolog
review
necropsi
howev
interpret
histolog
cat
equivoc
histolog
pattern
describ
multicentr
infiltr
associ
prolifer
author
conclud
like
lymphoprolif
disord
elimin
aberr
immun
respons
cat
diagnosi
lymphomalymphocyt
leukemia
made
within
week
onset
imha
potenti
trigger
secondari
imha
describ
second
cat
episod
imha
describ
potenti
associ
experiment
herp
viru
infect
potenti
associ
experiment
felv
infect
studi
neither
method
diagnosi
subtyp
lymphoma
specifi
evid
causal
associ
imha
lymphoma
low
median
ime
valu
rang
singl
cat
multipl
myeloma
imha
studi
show
causal
associ
neoplasia
imha
method
diagnosi
neoplasia
unclear
evid
associ
imha
multipl
myeloma
neglig
ime
valu
three
cat
cat
myeloprolif
imha
identifi
studi
demonstr
causal
associ
imha
neoplasia
report
cat
erythroleukemia
suggest
diagnosi
base
bone
marrow
cytolog
histolog
review
method
diagnosi
neoplasia
describ
third
cat
cat
myeloprolif
diseas
diagnosi
base
bone
marrow
examin
detail
cat
myeloprolif
diseas
felv
evid
causal
associ
erythroleukemia
imha
neglig
ime
valu
studi
could
assign
studi
erythroleukemia
unspecifi
myeloproliferar
diseas
yield
ime
valu
presenc
comorbid
singl
cat
histiocyt
sarcoma
imha
studi
show
causal
associ
imha
neoplasia
method
diagnosi
neoplasia
describ
yield
ime
valu
singl
case
pancreat
singl
case
anaplast
giant
cell
cat
imha
identifi
neither
studi
show
causal
associ
imha
neoplasia
evid
causal
associ
imha
carcinoma
sarcoma
neglig
ime
valu
case
one
cat
imha
uncharacter
gastrointestin
cat
imha
uncharacter
identifi
causal
associ
imha
lesion
identifi
method
diagnosi
presum
neoplast
lesion
describ
evid
causal
associ
imha
uncharacter
gastrointestin
neoplasia
low
ime
valu
neglig
uncharacter
mass
ime
valu
current
strong
evid
exist
causal
link
cancer
imha
cat
studi
need
determin
associ
exist
nevertheless
retrospect
evid
suggest
rel
high
preval
concurr
cancer
cat
imha
evid
pancreat
caus
imha
neglig
dog
neglig
low
cat
addit
studi
would
requir
establish
causal
relationship
evid
necrosi
caus
imha
neglig
dog
report
cat
anecdot
report
suggest
gener
inflammatori
process
induc
imha
dog
cat
direct
evid
lack
studi
determin
whether
inflammatori
process
caus
imha
warrant
seventeen
studi
describ
dog
imha
expos
drug
report
case
suffici
primari
data
calcul
ime
major
case
dog
expos
antimicrobi
case
ime
valu
rang
median
figur
highest
level
evid
ime
valu
came
unblind
random
prospect
clinic
trial
dog
given
escal
dose
cefazedon
acquir
remain
report
case
associ
low
neglig
evid
support
drug
toxin
caus
imha
dog
figur
preval
imha
dog
cat
either
rare
underreport
howev
lack
evid
preclud
possibl
drug
toxin
trigger
imha
consid
wide
practic
vaccin
lack
conclus
evid
associ
imha
current
vaccin
strategi
gener
safe
patient
individu
assess
risk
benefit
vaccin
studi
need
determin
imha
occur
dog
cat
develop
better
method
diagnosi
diseas
thorough
histori
document
vaccin
travel
exposur
flea
tick
flea
tick
prevent
heartworm
test
prevent
recommend
thorough
physic
examin
includ
retin
examin
perform
laboratori
screen
includ
cbc
blood
film
examin
clinic
pathologist
equival
train
hematologist
serum
biochem
profil
routin
urinalysi
urin
cultur
fecal
flotat
centrifug
also
consid
abdomin
radiograph
import
elimin
hemolysi
caus
zinc
toxic
imag
diagnost
test
screen
cancer
remain
reason
compon
diagnost
evalu
imha
dog
cat
perform
discret
attend
clinician
basi
likelihood
cancer
individu
patient
routin
test
pancreat
dog
cat
imha
recommend
unless
clinic
present
suggest
credibl
differenti
diagnosi
histori
help
assess
like
risk
certain
infect
thorough
physic
examin
diagnost
imag
help
identifi
potenti
nidu
infect
presenc
neoplast
lesion
pattern
abnorm
identifi
cbc
serum
biochemistri
urinalysi
increas
index
suspicion
specif
infecti
agent
may
associ
minimum
databas
also
identifi
addit
patholog
process
eg
proteinuria
may
requir
specif
treatment
although
insensit
blood
smear
examin
use
identifi
presenc
diseas
agent
although
evid
associ
urinari
tract
infect
caus
imha
neglig
identif
treatment
infect
immunosuppress
prudent
refer
reader
acvim
consensu
statement
treatment
imha
press
recommend
addit
discuss
specif
circumst
treat
subclin
bacteriuria
immunosuppress
patient
evid
gastrointestin
parasit
caus
imha
dog
low
rapid
resolut
imha
treatment
minim
immunosuppress
describ
support
inform
imag
help
identifi
neoplasia
nidu
infect
dog
imha
screen
infect
babesia
spp
use
combin
test
serolog
polymeras
chain
reaction
pcr
repeat
test
mean
pcr
perform
dog
origin
test
neg
high
risk
infect
base
breed
exposur
risk
sensit
pcr
serolog
test
may
vari
depend
laboratori
test
design
infect
piroplasm
includ
rangelia
theileria
speci
elimin
endem
area
immiti
infect
associ
anemia
posit
coomb
test
result
dog
screen
immiti
endem
area
travel
area
occur
studi
determin
diseas
agent
caus
imha
requir
definit
screen
recommend
made
addit
organ
howev
screen
addit
pathogen
particular
anaplasma
spp
bartonella
spp
ehrlichia
spp
endem
area
leishmania
spp
strongli
consid
potenti
foci
infect
identifi
initi
screen
investig
discret
attend
clinician
evid
babesia
spp
induc
imha
intermedi
high
infect
b
gibsoni
rule
transmiss
b
gibsoni
fight
breed
bite
wound
vertic
howev
tick
transmiss
haemaphysali
spp
possibl
rhipicephalu
sanguineu
occur
experiment
infect
mix
breed
dog
result
therefor
screen
b
gibsoni
breed
imha
prudent
b
voge
rule
dog
histori
exposur
r
sanguineu
retir
race
greyhound
dog
increas
risk
infect
common
occurr
r
sanguineu
infest
race
test
b
cani
b
rossi
mean
serolog
pcr
perform
endem
area
dog
live
california
coyot
hunt
dog
specif
screen
b
conrada
mean
pcr
serolog
test
avail
although
evid
causat
lack
coomb
anemia
commonli
document
dog
heartworm
diseas
bartonellosi
leishmaniosi
support
inform
gener
principl
optim
use
serolog
pcr
diagnos
diseas
summar
support
inform
gener
combin
pcr
serolog
test
enhanc
repeat
test
includ
repeat
pcr
addit
sampl
pairwis
serolog
test
demonstr
chang
acut
convalesc
titer
also
necessari
document
infect
mani
polymeras
chain
reaction
test
b
feli
perform
cat
endem
area
suggest
clinic
sign
serolog
test
avail
time
write
combin
test
would
optim
base
studi
babesia
speci
infect
dog
polymeras
chain
reaction
test
haemof
perform
cat
imha
studi
need
determin
whether
infect
hemotrop
mycoplasma
speci
associ
imha
immunosuppress
coinfect
cat
test
speci
prefer
possibl
sick
cat
test
felv
fiv
infect
accord
american
associ
felin
practition
retroviru
manag
guidelin
http
wwwcatvetscomguidelinespracticeguidelinesretrovirusmanagementguidelin
screen
cat
imha
felv
use
antigen
elisa
provir
felv
dna
quantit
pcr
test
may
help
confirmatori
test
routin
test
felin
coronaviru
mycoplasma
spp
cat
imha
recommend
appropri
diagnost
test
consid
cat
compat
clinic
sign
identif
babesia
spp
light
microscopi
blood
smear
consid
insensit
screen
cat
polymeras
chain
reaction
identifi
parasit
dna
rna
high
level
evid
found
haemof
caus
imha
cat
coinfect
host
immun
statu
may
play
role
develop
imha
cat
infect
less
pathogen
hemotrop
mycoplasma
spp
addit
coinfect
multipl
hemotrop
mycoplasma
speci
therefor
infect
less
pathogen
speci
may
signal
repeat
test
haemof
warrant
mycoplasma
infect
describ
cat
howev
pneumonia
caus
cold
agglutinin
hemolyt
anemia
peopl
infect
mycoplasma
cyno
associ
develop
cold
agglutinin
therefor
consid
possibl
trigger
cat
imha
find
compat
infect
evid
felv
associ
imha
cat
neglig
intermedi
polymeras
chain
reaction
test
provir
dna
could
consid
part
infecti
diseas
screen
overal
evid
fip
induc
imha
neglig
howev
given
immun
mechan
underli
effus
fip
test
fip
cat
compat
clinic
laboratori
find
judici
insuffici
evid
recommend
withhold
necessari
medic
dog
cat
imha
howev
medic
particularli
previous
implic
diseas
use
caution
patient
imha
everi
patient
ideal
complet
histori
record
includ
vaccin
drug
administ
dose
date
frequenc
durat
rout
administr
inform
product
use
manufactur
indic
specif
lot
advers
event
exposur
toxin
also
document
dog
cat
imha
evid
cefazedon
propylthiouracil
suggest
class
drug
may
associ
imha
small
anim
commonli
prescrib
medic
evid
neglig
specif
document
vaccin
histori
prospect
studi
may
help
determin
whether
vaccin
trigger
imha
date
approxim
dog
diagnosi
imha
vaccin
histori
vaccin
within
day
imha
diagnosi
howev
studi
compar
preval
adequ
control
limit
inconclus
anim
imha
risk
recurr
anemia
make
care
decis
risk
benefit
revaccin
import
everi
case
anim
receiv
immunosuppress
treatment
less
like
mount
protect
immun
routin
vaccin
base
data
analyz
propos
unifi
model
pathogenesi
imha
new
system
nomenclatur
diseas
categor
associ
rather
primari
secondari
respect
figur
b
clarif
need
word
primari
impli
trigger
definit
rule
wherea
secondari
impli
causat
propos
term
associ
use
comorbid
identifi
case
comorbid
might
caus
imha
secondari
imha
wherea
other
might
coincident
primari
imha
imha
case
comorbid
identifi
diagnost
evalu
includ
primari
idiopath
cryptogen
case
latter
impli
underli
caus
identifi
perhap
underli
pathomechan
current
understood
comorbid
could
detect
use
avail
test
vcci
task
forc
form
began
identifi
focus
question
repres
import
problem
veterinari
immunolog
name
evid
infect
neoplasia
drug
vaccin
comorbid
caus
imha
dog
cat
origin
intent
perform
systemat
review
literatur
answer
question
howev
quickli
becam
appar
studi
veterinari
literatur
design
determin
given
comorbid
caus
imha
henc
expand
approach
use
evalu
evid
present
review
critic
need
prospect
clinic
studi
directli
ask
question
whether
infect
neoplasia
drug
vaccin
caus
imha
comorbid
like
caus
imha
larg
number
affect
patient
infect
express
epitop
mimick
erythrocyt
antigen
wide
express
popul
organ
caus
transient
express
normal
hidden
epitop
other
might
induc
imha
patient
epigenet
genet
predisposit
given
inflammatori
context
studi
investig
individu
comorbid
trigger
imha
role
genet
epigenet
help
identifi
diseas
screen
patient
diseas
screen
select
patient
may
increas
risk
develop
imha
trigger
mechanist
studi
also
determin
comorbid
treat
lead
resolut
imha
without
need
immunosuppress
stringent
criteria
diagnosi
imha
definit
diagnosi
comorbid
must
integr
studi
design
order
make
meaning
observ
jonathan
fogl
paid
merial
speak
engag
continu
educ
linda
kidd
paid
speaker
idexx
zoeti
occasion
consult
idexx
zoeti
merck
author
conflict
interest
declar
author
declar
use
antimicrobi
author
declar
iacuc
approv
need
author
declar
human
ethic
approv
need
studi
